Cell-Penetrating Pepducin Therapy Targeting PAR1 in Supjects with Coronary Artery Disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 1, 2016, Pages 189-197

  Gurbel, Paul A ^a   Bliden, Kevin P ^a   Turner, Susan E ^b   Tantry, Udaya S ^a   Gesheff, Martin G ^a   Barr, Travis P ^b   Covic, Lidija ^b   Kuliopulos, Athan ^b  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

aspirin; collagen; coronary artery disease; lipopeptides; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEINASE ACTIVATED RECEPTOR 1; PZ 128; UNCLASSIFIED DRUG; CELL PENETRATING PEPTIDE; LIPOPEPTIDE; PZ-128 PEPTIDE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MALE; PERCUTANEOUS CORONARY INTERVENTION; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN TARGETING; SMOKING; THROMBOCYTE AGGREGATION; VOLUME OF DISTRIBUTION; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING PARAMETERS; CLINICAL TRIAL; DRUG EFFECTS; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; THROMBOCYTE; TREATMENT OUTCOME;

ADULT; AGED; BLOOD PLATELETS; CELL-PENETRATING PEPTIDES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPEPTIDES; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RECEPTOR, PAR-1; TREATMENT OUTCOME;

EID: 84952637415     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306777     Document Type: Article

References (36)

1. Gurbel PA, Bliden KP, Zaman KA, Yoho JA, Hayes KM, Tantry US, Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. Circulation 2005 111 1153 1159. doi: 10.1161/01.CIR.0000157138.02645.11
2. Gurbel PA, Tantry US, Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation 2012 125 1276 1287. doi: 10.1161/CIRCULATIONAHA.111.031195
3. Gurbel PA, Kuliopulos A, Tantry US, G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol 2015 35 500 512. doi: 10.1161/ATVBAHA.114.303412
4. Leger AJ, Covic L, Kuliopulos A, Protease-activated receptors in cardiovascular diseases. Circulation 2006 114 1070 1077. doi: 10.1161/CIRCULATIONAHA.105.574830
5. Kimmelstiel C, Zhang P, Kapur NK, Weintraub A, Krishnamurthy B, Castaneda V, Covic L, Kuliopulos A, Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011 4 171 179. doi: 10.1161/CIRCINTERVENTIONS.110.959098
6. Edelstein LC, Simon LM, Montoya RT, Holinstat M, Chen ES, Bergeron A, Kong X, Nagalla S, Mohandas N, Cohen DE, Dong JF, Shaw C, Bray PF, Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c. Nat Med 2013 19 1609 1616. doi: 10.1038/nm.3385
7. Scarborough RM, Kleiman NS, Phillips DR, Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999 100 437 444
8. Kimmelstiel C, Badar J, Covic L, Waxman S, Weintraub A, Jacques S, Kuliopulos A, Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thromb Res 2005 116 55 66. doi: 10.1016/j.thromres.2004.11.011
9. Zhang P, Gruber A, Kasuda S, Kimmelstiel C, O'Callaghan K, Cox DH, Bohm A, Baleja JD, Covic L, Kuliopulos A, Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation 2012 126 83 91. doi: 10.1161/CIRCULATIONAHA.112.091918
10. Alexander KP, Peterson ED, Minimizing the risks of anticoagulants and platelet inhibitors. Circulation 2010 121 1960 1970. doi: 10.1161/CIRCULATIONAHA.109.853135
11. Wallentin L, Becker RC, Budaj A, PLATO Investigators Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009 361 1045 1057. doi: 10.1056/NEJMoa0904327
12. Tantry US, Bonello L, Aradi D, Working Group on On-Treatment Platelet Reactivity Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013 62 2261 2273. doi: 10.1016/j.jacc.2013.07.101
13. Aradi D, Kirtane A, Bonello L, Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. Eur Heart J 2015 36 1762 1771. doi: 10.1093/eurheartj/ehv104
14. Stone GW, Witzenbichler B, Weisz G, ADAPT-DES Investigators Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013 382 614 623. doi: 10.1016/S0140-6736(13)61170-8
15. Amsterdam EA, Wenger NK, Brindis RG, American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014 64 e139 e228. doi: 10.1016/j.jacc.2014.09.017
16. Leger AJ, Jacques SL, Badar J, Kaneider NC, Derian CK, Andrade-Gordon P, Covic L, Kuliopulos A, Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 2006 113 1244 1254. doi: 10.1161/CIRCULATIONAHA.105.587758
17. Becker RC, Moliterno DJ, Jennings LK, Pieper KS, Pei J, Niederman A, Ziada KM, Berman G, Strony J, Joseph D, Mahaffey KW, Van de Werf F, Veltri E, Harrington RA, TRA-PCI Investigators Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009 373 919 928. doi: 10.1016/S0140-6736(09)60230-0
18. Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL, J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J 2010 31 2601 2613. doi: 10.1093/eurheartj/ehq320
19. Tricoci P, Huang Z, Held C, TRACER Investigators Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012 366 20 33. doi: 10.1056/NEJMoa1109719
20. Covic L, Misra M, Badar J, Singh C, Kuliopulos A, Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 2002 8 1161 1165. doi: 10.1038/nm760
21. Kaneider NC, Leger AJ, Agarwal A, Nguyen N, Perides G, Derian C, Covic L, Kuliopulos A, 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol 2007 8 1303 1312. doi: 10.1038/ni1525
22. Zhang P, Leger AJ, Baleja JD, Rana R, Corlin T, Nguyen N, Koukos G, Bohm A, Covic L, Kuliopulos A, Allosteric activation of a G protein-coupled receptor with cell-penetrating receptor mimetics. J Biol Chem 2015 290 15785 15798. doi: 10.1074/jbc.M115.636316
23. Covic L, Gresser AL, Talavera J, Swift S, Kuliopulos A, Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc Natl Acad Sci USA 2002 99 643 648. doi: 10.1073/pnas.022460899
24. O'Callaghan K, Kuliopulos A, Covic L, Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J Biol Chem 2012 287 12787 12796. doi: 10.1074/jbc.R112.355461
25. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp RE, Yamamoto M, Miyano M, Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000 289 739 745
26. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP, Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008 455 497 502. doi: 10.1038/nature07330
27. Zhang C, Srinivasan Y, Arlow DH, Fung JJ, Palmer D, Zheng Y, Green HF, Pandey A, Dror RO, Shaw DE, Weis WI, Coughlin SR, Kobilka BK, High-resolution crystal structure of human protease-activated receptor 1. Nature 2012 492 387 392. doi: 10.1038/nature11701
28. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A, Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009 137 332 343. doi: 10.1016/j.cell.2009.02.018
29. Tressel SL, Koukos G, Tchernychev B, Jacques SL, Covic L, Kuliopulos A, Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol Biol 2011 683 259 275. doi: 10.1007/978-1-60761-919-2-19
30. Fontanini KB, Janz J, Looby R, Hamilton JA, Rapid binding and transmembrane diffusion of pepducins in phospholipid bilayers. Biophysical J 2010 98 278a
31. van Geffen JP, Kleinegris MC, Verdoold R, Baaten CC, Cosemans JM, Clemetson KJ, Ten Cate H, Roest M, de Laat B, Heemskerk JW, Normal platelet activation profile in patients with peripheral arterial disease on aspirin. Thromb Res 2015 135 513 520. doi: 10.1016/j.thromres.2014.12.029
32. Hosokawa K, Ohnishi T, Miura N, Sameshima H, Koide T, Tanaka KA, Maruyama I, Antithrombotic effects of PAR1 and PAR4 antagonists evaluated under flow and static conditions. Thromb Res 2014 133 66 72. doi: 10.1016/j.thromres.2013.10.037
33. Storey RF, Kotha J, Smyth SS, Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy. Thromb Haemost 2014 111 883 891. doi: 10.1160/TH13-07-0624
34. O'Donoghue ML, Bhatt DL, Wiviott SD, Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation 2011 123 1843 1853
35. Wiviott SD, Flather MD, O'Donoghue ML, Goto S, Fitzgerald DJ, Cura F, Aylward P, Guetta V, Dudek D, Contant CF, Angiolillo DJ, Bhatt DL, LANCELOT-CAD Investigators Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin-Coronary Artery Disease Trial. Circulation 2011 123 1854 1863. doi: 10.1161/CIRCULATIONAHA.110.001404
36. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US, Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005 46 1820 1826. doi: 10.1016/j.jacc.2005.07.041